← Back to Search

Nicotine Replacement

Vaping vs. Nicotine Replacement for Smoking Behavior

N/A

Recruiting

Led By Theodore L Wagener, PhD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

>= 21 years old

Be older than 18 years old

Must not have

Serious angina pectoris or chest pain

Diagnosed medical conditions of lung disease, asthma, cystic fibrosis, heart disease or chronic obstructive pulmonary disease (COPD)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 2, 6, 14, and 26 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial compares tobacco flavored electronic cigarettes to non-tobacco flavored electronic cigarettes and nicotine replacement therapy (patches and lozenges) in current cigarette smokers. The goal is to see if ECs

Who is the study for?

This trial is for current cigarette smokers who are interested in trying electronic cigarettes (ECs) or nicotine replacement therapy to reduce smoking. Specific eligibility criteria details were not provided, so it's unclear who exactly can or cannot participate.

What is being tested?

The study compares the impact of tobacco-flavored ECs versus non-tobacco flavored ECs and traditional nicotine replacements on smoking habits. It aims to see if different flavors affect the appeal and usage of ECs, as well as their effectiveness in reducing cigarette cravings and dependence.

What are the potential side effects?

Potential side effects may include irritation from vaping, possible nicotine withdrawal symptoms when switching from cigarettes to ECs or NRT, and typical reactions to nicotine replacements like skin irritation from patches or mouth issues from lozenges.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 21 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I experience severe chest pain.

Select...

I have a diagnosed condition like asthma, COPD, heart or lung disease.

Select...

My high blood pressure is not controlled by medication.

Select...

I have not had a stroke in the last three months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 2, 6, 14, and 26 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 2, 6, 14, and 26 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 2, 6, 14, and 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Biochemically verified 7-day point prevalence abstinence from cigarettes

Switching rate

Secondary study objectives

Change in nicotine dependence

Changes in cigarette craving and nicotine withdrawal

Cigarettes smoked per day

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Arm II (TEC)Experimental Treatment2 Interventions

Participants receive TEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.

Group II: Arm I (PEC)Experimental Treatment2 Interventions

Participants receive PEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.

Group III: Arm III (NRT)Active Control2 Interventions

Participants receive NRT (nicotine patches and lozenges) for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.

0 / 5Eligibility criteria met